{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:37:41Z","timestamp":1793342261039,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82188102"],"award-info":[{"award-number":["82188102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273453"],"award-info":[{"award-number":["82273453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Esophageal squamous cell carcinoma (ESCC) evolves within a highly interactive tumor microenvironment (TME) that shapes therapeutic response. We utilized mass cytometry to analyze over 10 million cells from 25 ESCC tumors, 24 adjacent nontumor tissues, and 23 peripheral blood samples, employing an extensive panel of 42 immune markers. The resulting atlas reveals a compartmentalized landscape with a reproducible paucity of CD4\u207a and CD8\u207a central memory T cells (TCM) in tumor sites. Reintroduction of patient-derived TCMs restored antitumor immunity in coculture assays, demonstrating their cytotoxic capacity in vitro and suggesting their potential relevance for future therapeutic exploration. Myeloid profiling identified PD-L1\u207a tumor-associated macrophages (TAMs) as correlates of clinical benefit; ex vivo PD-L1 blockade reprogrammed TAMs toward proinflammatory states, indicating pharmacological malleability. Notably, CD39\u207a tumor-infiltrating T cells were consistently associated with favorable prognosis and increased responsiveness to PD-1 blockade across cancer types. The functional inhibition of CD39 impaired cytotoxic T-cell activity, underscoring its dual role as a marker of immune dysfunction and a promising therapeutic target. Collectively, our findings provide a comprehensive immune landscape of ESCC, highlighting key immunological deficits and opportunities for targeted interventions. The insights gained underscore the potential of tailoring immunotherapies to the specific immune profiles of the TME, potentially revolutionizing treatment paradigms for ESCC patients. This study sets the stage for a more nuanced understanding and manipulation of the immune elements critical for optimizing cancer immunotherapy.<\/jats:p>","DOI":"10.1038\/s41392-025-02446-x","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:02:34Z","timestamp":1760914954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Single-cell atlas of the esophageal squamous cell carcinoma immune ecosystem to predict immunotherapy response"],"prefix":"10.1038","volume":"10","author":[{"given":"Xiankai","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-033X","authenticated-orcid":false,"given":"Zhihua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"2446_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2446_CR2","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1097\/CM9.0000000000003420","volume":"137","author":"L Qi","year":"2024","unstructured":"Qi, L. et al. Global esophageal cancer epidemiology in 2022 and predictions for 2050: A comprehensive analysis and projections based on GLOBOCAN data. Chin. Med J. (Engl.) 137, 3108\u20133116 (2024).","journal-title":"Chin. Med J. (Engl.)"},{"key":"2446_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","volume":"541","author":"N Cancer Genome Atlas Research","year":"2017","unstructured":"Cancer Genome Atlas Research, N. et al. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169\u2013175 (2017).","journal-title":"Nature"},{"key":"2446_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41392-023-01428-1","volume":"8","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. RPS15 interacted with IGF2BP1 to promote esophageal squamous cell carcinoma development via recognizing m(6)A modification. Signal Transduct. Target Ther. 8, 224 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2446_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2022.12.004","volume":"41","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer Cell 41, 181\u2013195.e189 (2023).","journal-title":"Cancer Cell"},{"key":"2446_CR6","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41422-020-0333-6","volume":"30","author":"Y Cui","year":"2020","unstructured":"Cui, Y. et al. Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma. Cell Res. 30, 902\u2013913 (2020).","journal-title":"Cell Res."},{"key":"2446_CR7","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3390\/cancers11081156","volume":"11","author":"L Lin","year":"2019","unstructured":"Lin, L. & Lin, D. C. Biological Significance of Tumor Heterogeneity in Esophageal Squamous Cell Carcinoma. Cancers (Basel) 11, 1156 (2019).","journal-title":"Cancers (Basel)"},{"key":"2446_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20019-0","volume":"11","author":"Y Zheng","year":"2020","unstructured":"Zheng, Y. et al. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nat. Commun. 11, 6268 (2020).","journal-title":"Nat. Commun."},{"key":"2446_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104281","volume":"84","author":"W Guo","year":"2022","unstructured":"Guo, W. et al. Integrating microarray-based spatial transcriptomics and single-cell RNA-sequencing reveals tissue architecture in esophageal squamous cell carcinoma. EBioMedicine 84, 104281 (2022).","journal-title":"EBioMedicine"},{"key":"2446_CR10","doi-asserted-by":"publisher","first-page":"e007847","DOI":"10.1136\/jitc-2023-007847","volume":"11","author":"D Han","year":"2023","unstructured":"Han, D. et al. High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy. J. Immunother. Cancer 11, e007847 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2446_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1370801","volume":"14","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Immune cell related signature predicts prognosis in esophageal squamous cell carcinoma based on single-cell and bulk-RNA sequencing. Front Oncol. 14, 1370801 (2024).","journal-title":"Front Oncol."},{"key":"2446_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nm.4086","volume":"22","author":"T Saito","year":"2016","unstructured":"Saito, T. et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. 22, 679\u2013684 (2016).","journal-title":"Nat. Med."},{"key":"2446_CR13","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni, D., Angell, H. K. & Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662\u2013680 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"2446_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","volume":"20","author":"A Kallies","year":"2020","unstructured":"Kallies, A., Zehn, D. & Utzschneider, D. T. Precursor exhausted T cells: key to successful immunotherapy?. Nat. Rev. Immunol. 20, 128\u2013136 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2446_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.immuni.2014.01.005","volume":"40","author":"A Crawford","year":"2014","unstructured":"Crawford, A. et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity 40, 289\u2013302 (2014).","journal-title":"Immunity"},{"key":"2446_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101420","volume":"5","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer. Cell Rep. Med. 5, 101420 (2024).","journal-title":"Cell Rep. Med."},{"key":"2446_CR17","doi-asserted-by":"publisher","first-page":"844142","DOI":"10.3389\/fimmu.2022.844142","volume":"13","author":"B Lv","year":"2022","unstructured":"Lv, B. et al. Immunotherapy: Reshape the Tumor Immune Microenvironment. Front Immunol. 13, 844142 (2022).","journal-title":"Front Immunol."},{"key":"2446_CR18","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/s41416-023-02238-6","volume":"128","author":"H Elomaa","year":"2023","unstructured":"Elomaa, H. et al. Spatially resolved multimarker evaluation of CD274 (PD-L1)\/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer. Br. J. Cancer 128, 2104\u20132115 (2023).","journal-title":"Br. J. Cancer"},{"key":"2446_CR19","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3390\/cancers15041184","volume":"15","author":"M Liu","year":"2023","unstructured":"Liu, M. et al. CD39-Expressing CD8(+) T Cells as a New Molecular Marker for Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma. Cancers (Basel) 15, 1184 (2023).","journal-title":"Cancers (Basel)"},{"key":"2446_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53262-w","volume":"15","author":"K Tanoue","year":"2024","unstructured":"Tanoue, K. et al. Spatial dynamics of CD39(+)CD8(+) exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer. Nat. Commun. 15, 9033 (2024).","journal-title":"Nat. Commun."},{"key":"2446_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05072-0","volume":"9","author":"T Duhen","year":"2018","unstructured":"Duhen, T. et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat. Commun. 9, 2724 (2018).","journal-title":"Nat. Commun."},{"key":"2446_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nprot.2015.020","volume":"10","author":"ER Zunder","year":"2015","unstructured":"Zunder, E. R. et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat. Protoc. 10, 316\u2013333 (2015).","journal-title":"Nat. Protoc."},{"key":"2446_CR23","doi-asserted-by":"publisher","first-page":"e005887","DOI":"10.1126\/scitranslmed.aaw8718","volume":"11","author":"AS Woodward Davis","year":"2019","unstructured":"Woodward Davis, A. S. et al. The human tissue-resident CCR5(+) T cell compartment maintains protective and functional properties during inflammation. Sci. Transl. Med 11, e005887 (2019).","journal-title":"Sci. Transl. Med"},{"key":"2446_CR24","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell 171, 934\u2013949.e916 (2017).","journal-title":"Cell"},{"key":"2446_CR25","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s12276-020-00493-8","volume":"52","author":"JW Cho","year":"2020","unstructured":"Cho, J. W. et al. Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer. Exp. Mol. Med. 52, 1550\u20131563 (2020).","journal-title":"Exp. Mol. Med."},{"key":"2446_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52977-0","volume":"15","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. Nat. Commun. 15, 9097 (2024).","journal-title":"Nat. Commun."},{"key":"2446_CR27","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.ccell.2023.09.011","volume":"41","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Progenitor-like exhausted SPRY1(+)CD8(+) T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. Cancer Cell 41, 1852\u20131870.e1859 (2023).","journal-title":"Cancer Cell"},{"key":"2446_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"2446_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1\/Anti-CTLA-4 Combined Therapy. Cancer Cell 35, 238\u2013255.e236 (2019).","journal-title":"Cancer Cell"},{"key":"2446_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature14282","volume":"522","author":"SB Coffelt","year":"2015","unstructured":"Coffelt, S. B. et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345\u2013348 (2015).","journal-title":"Nature"},{"key":"2446_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ijc.30134","volume":"139","author":"RS Patil","year":"2016","unstructured":"Patil, R. S. et al. IL17 producing gammadeltaT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int J. Cancer 139, 869\u2013881 (2016).","journal-title":"Int J. Cancer"},{"key":"2446_CR32","doi-asserted-by":"publisher","first-page":"1098847","DOI":"10.3389\/fimmu.2023.1098847","volume":"14","author":"AM Corsale","year":"2023","unstructured":"Corsale, A. M., Di Simone, M., Lo Presti, E., Dieli, F. & Meraviglia, S. gammadelta T cells and their clinical application in colon cancer. Front Immunol. 14, 1098847 (2023).","journal-title":"Front Immunol."},{"key":"2446_CR33","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775\u2013790 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2446_CR34","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.21037\/jtd-22-1696","volume":"14","author":"L Shao","year":"2022","unstructured":"Shao, L. et al. In lung adenocarcinoma, low expression of the cell surface extracellular nucleotidase CD39 is related to immune infiltration and a poor prognosis. J. Thorac. Dis. 14, 4938\u20134950 (2022).","journal-title":"J. Thorac. Dis."},{"key":"2446_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00262-024-03799-y","volume":"73","author":"SL Hill","year":"2024","unstructured":"Hill, S. L. et al. High proportion of PD-1 and CD39 positive CD8+ tissue resident T lymphocytes correlates with better clinical outcome in resected human oesophageal adenocarcinoma. Cancer Immunol. Immunother. 73, 213 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"2446_CR36","doi-asserted-by":"publisher","first-page":"e005887","DOI":"10.1136\/jitc-2022-005887","volume":"11","author":"J van den Bulk","year":"2023","unstructured":"van den Bulk, J. et al. CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden. J. Immunother. Cancer 11, e005887 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2446_CR37","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1158\/1078-0432.CCR-20-4394","volume":"27","author":"CM Laumont","year":"2021","unstructured":"Laumont, C. M. et al. Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer. Clin. Cancer Res 27, 4089\u20134100 (2021).","journal-title":"Clin. Cancer Res"},{"key":"2446_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34495-z","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment. Nat. Commun. 13, 6740 (2022).","journal-title":"Nat. Commun."},{"key":"2446_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.682503","volume":"12","author":"X Ni","year":"2021","unstructured":"Ni, X. et al. A Novel Prognostic Biomarker of Luminal Breast Cancer: High CD39 Expression Is Related to Poor Survival. Front Genet 12, 682503 (2021).","journal-title":"Front Genet"},{"key":"2446_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107122","volume":"202","author":"Y Shen","year":"2024","unstructured":"Shen, Y. et al. CD39(hi) identifies an exhausted tumor-reactive CD8(+) T cell population associated with tumor progression in human gastric cancer. Pharm. Res. 202, 107122 (2024).","journal-title":"Pharm. Res."},{"key":"2446_CR41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13045-021-01207-x","volume":"14","author":"JC Lu","year":"2021","unstructured":"Lu, J. C. et al. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. J. Hematol. Oncol. 14, 200 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2446_CR42","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/onc.2012.269","volume":"32","author":"J Bastid","year":"2013","unstructured":"Bastid, J. et al. ENTPD1\/CD39 is a promising therapeutic target in oncology. Oncogene 32, 1743\u20131751 (2013).","journal-title":"Oncogene"},{"key":"2446_CR43","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20062512","volume":"204","author":"S Deaglio","year":"2007","unstructured":"Deaglio, S. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257\u20131265 (2007).","journal-title":"J. Exp. Med."},{"key":"2446_CR44","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles, J. R., Globig, A. M., Kaech, S. M. & Wherry, E. J. CD8(+) T cells in the cancer-immunity cycle. Immunity 56, 2231\u20132253 (2023).","journal-title":"Immunity"},{"key":"2446_CR45","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.3389\/fimmu.2019.02035","volume":"10","author":"TS Kapellos","year":"2019","unstructured":"Kapellos, T. S. et al. Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases. Front Immunol. 10, 2035 (2019).","journal-title":"Front Immunol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02446-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02446-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02446-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:02:35Z","timestamp":1760914955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02446-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2446"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02446-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"348"}}